{"id":"W3185437491","doi":"10.1016/s2213-8587(21)00174-1","title":"Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Discontinuation; Type 2 diabetes; Sulfonylurea; Internal medicine; Randomized controlled trial; Diabetes mellitus; Metformin; Physical therapy; Insulin; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000358274,0.0003452491,0.001276179,0.0001824445,0.00008400565,0.00002570961,0.0002099439,0.00008906716,0.00009102848],"category_scores_gemma":[0.0002381442,0.00023312,0.0001090966,0.0004613649,0.0003027901,0.00007963302,0.0002132244,0.0002946667,0.00001168836],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009971497,"about_ca_system_score_gemma":0.0001181475,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001512384,"about_ca_topic_score_gemma":0.0000393854,"domain_scores_codex":[0.9972156,0.0002026585,0.000537396,0.0004903161,0.0002874208,0.001266608],"domain_scores_gemma":[0.9980751,0.000711884,0.0002246874,0.0006990726,0.0001721635,0.0001171486],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8345184,0.002506715,0.1235974,0.0002433971,0.002094557,0.00008000671,0.0002447848,0.00002236144,0.0004580983,0.001159192,0.0007158251,0.03435935],"study_design_scores_gemma":[0.9497751,0.005758414,0.03421823,0.0001491368,0.001072497,7.875768e-7,0.0001312328,0.00006168475,0.003043389,0.0001050776,0.005431671,0.0002527621],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917504,0.001309049,0.000001763117,0.001588338,0.0003823377,0.002911636,0.00002454877,0.00006643141,0.001965541],"genre_scores_gemma":[0.9980116,0.0003207903,0.0002193812,0.0003626912,0.0002230093,0.0002296625,0.000251475,0.00004017741,0.0003412],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1152568,"threshold_uncertainty_score":0.9506359,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03327913042604658,"score_gpt":0.3050845420511496,"score_spread":0.271805411625103,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}